Drug Search Results

Saracatinib

Alternative Names: saracatinib, azd0530, saracatinab
Latest Update: 2024-07-30
Latest Update Note: News Article

Product Description

Mechanisms of Action: SRC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Saracatinib

Countries in Clinic: Germany, Netherlands, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Fibrodysplasia Ossificans Progressiva|Idiopathic Pulmonary Fibrosis|Myositis Ossificans

Trial	Phase	Trial Status	Disease	Primary Completion Date
STOPFOP	P2	Recruiting	Fibrodysplasia Ossificans Progressiva\|Myositis Ossificans	2025-05-06
STOP-IPF	P2	Active, not recruiting	Idiopathic Pulmonary Fibrosis	2024-09-15
STOPFOP	P2	Active, not recruiting	Unknown	2022-06-08

Recent News Events

Date	Type	Title
07/30/2024	News Article	New Study Describes a Functional, Aged, Human Cell-Based Platform That Examines the Contribution of Senescence in Alzheimer's Disease Progression, and Response to Therapeutics
05/02/2024	PubMed	Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.
04/22/2024	PubMed	Dual Drug Repurposing: The Example of Saracatinib.
03/14/2024	PubMed	Deficiency of Nuclear Receptor Coactivator 3 Aggravates Diabetic Kidney Disease by Impairing Podocyte Autophagy.
06/08/2023	News Article	Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
05/02/2023	News Article	Orphan drugs market to grow by USD 170.8 billion between 2022 and 2027; Growth driven by rising incidence of rare diseases - Technavio
01/17/2022	News Article	Global Idiopathic Pulmonary Fibrosis (IPF) Market Pipeline Report 2021 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions